Inhibiting Bone Turnover Could Prevent Bone Mets in Breast Cancer


An inhibitor of osteoclast formation can stop the proliferation of dormant tumor cells that in some breast cancer survivors turn into bone metastases.

An inhibitor of osteoclast formation could help prevent bone metastases

An inhibitor of osteoclast formation can stop the proliferation of dormant tumor cells that in some breast cancer survivors turn into bone metastases, according to a new study in the lab and in mice.

Disseminated tumor cells can be found in the bone marrow of breast cancer patients even several years after resection of the primary tumor. Most of those patients remain asymptomatic, but about 15% of them will develop overt bone metastases.

“One of the main unanswered questions in relation to initiation of bone metastasis is how changes to the bone microenvironment, including accelerated bone turnover, affects disseminated tumor cells in bone,” wrote researchers led by Penelope D. Ottewell, PhD, of the University of Sheffield in the United Kingdom. Her group tested whether interruption of the interaction between a protein called RANK and its ligand (RANKL), which is essential for osteoclastogenesis, could stop the proliferation of the dormant tumor cells. Results were published online ahead of print on February 2 in the International Journal of Cancer.

In an in vivo study involving mice, researchers administered OPG-Fc, which blocks the RANK-RANKL interactions. They tested this in some mice that had undergone ovariectomy, which is known to increase bone turnover and thus possibly initiate tumor cell proliferation. Fourteen mice in each of two groups were injected with either saline or with OPG-Fc, and half of each of those groups also had undergone ovariectomy. In the saline group, 78.5% of the ovariectomy mice developed long bone tumors by day 35; only 14.5% of those who underwent a sham ovariectomy procedure developed tumors.

The OPG-Fc, meanwhile, yielded even better results, with only 7% of those who underwent ovariectomy developing tumors compared to the 78.5% with saline and ovariectomy. “In addition, in the small number of animals in which tumors did grow in the bone OPG-Fc significantly reduced tumor size in both [ovariectomy] (P < .01) and sham [ovariectomy] (P < .01) operated mice,” the researchers wrote.

They pointed out that most women who develop bone metastases following breast cancer are postmenopausal. “These data indicate that inhibition of osteoclast activity may have specific anti-tumor effects in a low estrogen environment,” the investigators wrote. Early intervention with “anti-resorptive” therapy in such an environment should be considered, they concluded, as a way to prevent development of dangerous bone metastases.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content